Pharmacokinetics and pharmacodynamics of the leukotriene B4 receptor antagonist CP‐105,696 in man following single oral administration

Abstract

Aims CP-105,696, (+)-1-(3S,4R)-[3-(4-phenylbenzyl)-4-hydroxy-chroman-7-yl] cyclopropane carboxylic acid is a potent, novel LTB₄ receptor antagonist advanced to clinical trials to determine its efficacy in inflammatory diseases. The pharmacokinetics and pharmacodynamics of CP-105,696 were investigated in healthy male volunteers following oral administration of single doses of 5 to 640 mg. Methods Forty-eight subjects participated in a randomized, double-blind, parallel group study. Plasma and urine concentrations of CP-105,696 were determined at intervals after drug administration. As an indication of LTB₄ receptor antagonism following oral administration of CP-105,696, the inhibiton of LTB₄-induced upregulation of the neutrophil cell surface complement receptor (CR3), CD11b/CD18, was monitored at 4 h following drug administration using an ex vivo whole blood flow cytometry assay. Results C_max and AUC(0,∞) increased in a dose-related manner. Respective mean C_max values were 0.54 to 30.41 μg ml⁻¹ following doses of 5 to 640 mg. Respective mean AUC(0,∞) values were 1337 to 16819 μg ml⁻¹ h for the 40 to 640 mg dose groups. Plasma concentrations declined in a monoexponential manner, with terminal elimination half-lives ranging from 289 to 495 h. Group mean terminal elimination half-lives were dose-independent. Urinary excretion of unchanged drug accounted for 4-mediated CD11b upregulation on human neutrophils in whole blood. CP-105,696 plasma concentrations of 5–6 μg ml⁻¹ were necessary to elicit a two-fold shift to the right of the LTB₄ concentration response curve for CD11b upregulation. Conclusions These studies demonstrate pharmacologically significant LTB₄-receptor antagonism following a single dose of CP-105,696 and pharmacokinetics consistent with once-daily dosing.